[go: up one dir, main page]

ZA200905677B - Protein formulations containing sorbitol - Google Patents

Protein formulations containing sorbitol

Info

Publication number
ZA200905677B
ZA200905677B ZA200905677A ZA200905677A ZA200905677B ZA 200905677 B ZA200905677 B ZA 200905677B ZA 200905677 A ZA200905677 A ZA 200905677A ZA 200905677 A ZA200905677 A ZA 200905677A ZA 200905677 B ZA200905677 B ZA 200905677B
Authority
ZA
South Africa
Prior art keywords
formulations containing
protein formulations
containing sorbitol
sorbitol
protein
Prior art date
Application number
ZA200905677A
Other languages
English (en)
Inventor
David C Sek
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200905677B publication Critical patent/ZA200905677B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA200905677A 2007-02-16 2009-08-14 Protein formulations containing sorbitol ZA200905677B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90181107P 2007-02-16 2007-02-16

Publications (1)

Publication Number Publication Date
ZA200905677B true ZA200905677B (en) 2010-05-26

Family

ID=39402540

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905677A ZA200905677B (en) 2007-02-16 2009-08-14 Protein formulations containing sorbitol

Country Status (12)

Country Link
US (1) US20080200655A1 (xx)
EP (1) EP2124889A2 (xx)
JP (1) JP2010519223A (xx)
KR (1) KR20090110349A (xx)
CN (1) CN101605532A (xx)
AU (1) AU2008216090A1 (xx)
CA (1) CA2675602A1 (xx)
IL (1) IL199863A0 (xx)
MX (1) MX2009008769A (xx)
RU (1) RU2009127888A (xx)
WO (1) WO2008101175A2 (xx)
ZA (1) ZA200905677B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527364A1 (en) * 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
MX2010012451A (es) 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
EP2399572A1 (en) * 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
US9458484B2 (en) 2010-10-22 2016-10-04 Bio-Rad Laboratories, Inc. Reverse transcriptase mixtures with improved storage stability
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
US11078265B2 (en) * 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
US11058768B2 (en) * 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
BR112017014684A2 (en) 2015-02-04 2018-01-09 Boehringer Ingelheim International Gmbh methods of treatment of inflammatory diseases
US20190046642A1 (en) 2016-02-23 2019-02-14 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
CN110463819A (zh) * 2019-09-16 2019-11-19 东北农业大学 一种通过电解及糖醇化合物改性米糠蛋白功能性质的方法
US20240026332A1 (en) * 2020-12-04 2024-01-25 Amano Enzyme Inc. Liquid enzyme preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148165T1 (de) * 1989-07-24 1997-02-15 Bayer Ag Stabilisierung von hochgereinigten proteinen
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab

Also Published As

Publication number Publication date
KR20090110349A (ko) 2009-10-21
CN101605532A (zh) 2009-12-16
MX2009008769A (es) 2009-08-25
IL199863A0 (en) 2010-04-15
RU2009127888A (ru) 2011-03-27
WO2008101175A3 (en) 2009-01-08
AU2008216090A1 (en) 2008-08-21
WO2008101175A2 (en) 2008-08-21
US20080200655A1 (en) 2008-08-21
CA2675602A1 (en) 2008-08-21
JP2010519223A (ja) 2010-06-03
EP2124889A2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
ZA200905677B (en) Protein formulations containing sorbitol
EP1988922A4 (en) PROTEIN FORMULATIONS
GB2435419B (en) Formulations
EP2225275A4 (en) PROTEIN FORMULATION
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
ZA200906699B (en) Insecticidal proteins
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
HUE046149T2 (hu) Fehérje
ZA200908969B (en) Formulations
IL211670A0 (en) Therapeutic protein formulations
GB0605780D0 (en) Formulations
GB0718409D0 (en) Formulations
GB0809979D0 (en) Formulations
GB0711957D0 (en) Formulations
GB0810232D0 (en) Formulations
GB0615108D0 (en) Novel formulations
GB0610336D0 (en) Formulations
GB0719231D0 (en) Protein
GB0718404D0 (en) Formulations
GB0711440D0 (en) Aqueous formulations
ZA200807682B (en) Novel formulations
GB0705179D0 (en) Formulations
GB0720563D0 (en) Protein
GB0710900D0 (en) Formulations